BTI
NBIX icon

Blue Trust Inc’s Neurocrine Biosciences NBIX Stock Holding History

Blue Trust Inc’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$208K Buy
1,235
+700
+131% +$104K ﹤0.01% 778
2026
Q1 		$70.5K Buy
535
+526
+5,844% +$69.8K ﹤0.01% 1177
2025
Q4 		$1.28K Hold
9
– – ﹤0.01% 2239
2025
Q3 		$1.26K Hold
9
– – ﹤0.01% 2271
2025
Q2 		$1.13K Hold
9
– – ﹤0.01% 2234
2025
Q1 		$995 Sell
9
-69
-88% -$8.74K ﹤0.01% 2294
2024
Q4 		$10.6K Sell
78
-270
-78% -$33.4K ﹤0.01% 1814
2024
Q3 		$47.9K Buy
348
+220
+172% +$30.2K ﹤0.01% 1584
2024
Q2 		$17.7K Buy
128
+79
+161% +$10.8K ﹤0.01% 1716
2024
Q1 		$6.76K Buy
49
+5
+11% +$683 ﹤0.01% 1558
2023
Q4 		$5K Buy
44
+28
+175% +$3.22K ﹤0.01% 1851
2023
Q3 		$2K Buy
+16
New +$1.69K ﹤0.01% 1827
2023
Q2 		– Sell
-30
Closed -$4K – 2353
2023
Q1 		$4K Buy
30
+12
+67% +$1.25K ﹤0.01% 1851
2022
Q4 		$2K Hold
18
– – ﹤0.01% 1942
2022
Q3 		$2K Buy
18
+5
+38% +$507 ﹤0.01% 1805
2022
Q2 		$1K Buy
+13
New +$1.2K ﹤0.01% 1802

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Blue Trust Inc's NBIX Position: Q2 2026 in Review

Blue Trust Inc increased its Neurocrine Biosciences (NBIX) stake by 131% in Q2 2026, buying an estimated $104K and bringing the position to 1,235 shares worth $208K. The position accounts for ﹤0.01% of the portfolio, ranked #778.

Blue Trust Inc first reported a position in NBIX in Q2 2022 and has held it in 16 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Blue Trust Inc held 1,235 shares of Neurocrine Biosciences worth $208K as of Q2 2026.
  • Blue Trust Inc bought 700 Neurocrine Biosciences shares in Q2 2026, an estimated $104K.
  • Neurocrine Biosciences made up ﹤0.01% of Blue Trust Inc's portfolio in Q2 2026, its #778 holding.
  • Blue Trust Inc first reported a position in Neurocrine Biosciences in Q2 2022 and has held it in 16 quarters since.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.